Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 14/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.38 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18306367 | 0.90 | AURKA (0.37) | PTGS2PTGS1MAP4K4AURKADAPK3 | |
| SCHEMBL18306344 | 0.90 | MAP4K4 (0.37) | PTGS2PTGS1MAP4K4AURKADAPK3 | |
| SCHEMBL18306348 | 0.90 | RPS6KA3 (0.37) | PTGS2PTGS1MAPK14MAP4K4AURKA | |
| SCHEMBL18306440 | 0.86 | AURKA (0.34) | PTGS2PTGS1MAP4K4AURKADAPK3 | |
| SCHEMBL24715961 | 0.84 | KDM1A (0.36) | MAP4K4AURKADAPK3JAK2PRKD3 | |
| SCHEMBL18306350 | 0.81 | TGFBR1 (0.39) | MAPK14MAP4K4AURKADAPK3JAK2 | |
| SCHEMBL18306360 | 0.81 | IRAK4 (0.35) | PTGS2PTGS1MAPK14MAP4K4AURKA | |
| SCHEMBL17177325 | 0.81 | ABL1 (0.36) | PTGS2PTGS1MAP4K4AURKADAPK3 | |
| SCHEMBL18306300 | 0.81 | USP7 (0.34) | PTGS2PTGS1PIM1GSK3ARPS6KA3 | |
| SCHEMBL18306349 | 0.79 | ADORA2B (0.41) | PTGS2PTGS1MAP4K4AURKADAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903978-B1 | GDF-8 INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2022-12-07 | — | — | EP | disclosed |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-20170342048-A1 | GDF-8 Inhibitors | MIDCAP FINANCIAL TRUST | 2017-11-30 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518040-B2 | GDF-8 inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233170-B2 | 2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use | TGFBR1, TGFBR2, ACVR1 | PTGS2 388/4885PTGS1 314/4885ABCC4 1871/4885 |
| US-20170342048-A1 | GDF-8 Inhibitors | MSTN, MYOF, CXCL8 | PTGS2 1658/4885PTGS1 762/4885ABCC4 3641/4885 |
| US-10858335-B2 | 2,3-Disubstituted pyridine compounds as TGF-β inhibitors and methods of use | SMAD3, TGFBR1, TGFBR2 | PTGS2 464/4885PTGS1 457/4885ABCC4 3209/4885 |
| US-20190284155-A1 | 2,3-Disubstituted Pyridine Compounds as TGF-Beta Inhibitors and Methods of Use | TGFBR2, ACVR1, TGFBR1 | PTGS2 506/4885PTGS1 528/4885ABCC4 3109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.